Table 1

Characteristics of the 6 recombinant FVIII products commercialized worldwide

ProductManufacturerDistributorBrand nameGenerationProduction cell lineProtein lengthHuman or animal proteins in fermentation processAlbumin as stabilizerMarketing authorization dates in EU
A Baxter Bioscience Baxter Healthcare Recombinate CHO Full Yes Yes June 17, 1993 
Aventis Behring Bioclate 
B Bayer HealthCare Bayer HealthCare Kogenate BHK Full Yes Yes June 15, 1994 
Aventis Behring Helixate 
C Wyeth Pharmaceuticals Wyeth Pharmaceuticals ReFacto CHO B-domain deleted Yes No April 13, 1999 
D Bayer HealthCare Bayer HealthCare Kogenate FS/Bayer BHK Full Yes No August 4, 2000 
CSL Behring Helixate NexGen 
E Baxter Bioscience Baxter Healthcare Advate CHO Full No No March 2, 2004 
F Pfizer Pfizer ReFacto AF CHO B-domain deleted No No April 15, 2009 
Xyntha (used outside the EU) 
ProductManufacturerDistributorBrand nameGenerationProduction cell lineProtein lengthHuman or animal proteins in fermentation processAlbumin as stabilizerMarketing authorization dates in EU
A Baxter Bioscience Baxter Healthcare Recombinate CHO Full Yes Yes June 17, 1993 
Aventis Behring Bioclate 
B Bayer HealthCare Bayer HealthCare Kogenate BHK Full Yes Yes June 15, 1994 
Aventis Behring Helixate 
C Wyeth Pharmaceuticals Wyeth Pharmaceuticals ReFacto CHO B-domain deleted Yes No April 13, 1999 
D Bayer HealthCare Bayer HealthCare Kogenate FS/Bayer BHK Full Yes No August 4, 2000 
CSL Behring Helixate NexGen 
E Baxter Bioscience Baxter Healthcare Advate CHO Full No No March 2, 2004 
F Pfizer Pfizer ReFacto AF CHO B-domain deleted No No April 15, 2009 
Xyntha (used outside the EU) 

EU, European Union.

Close Modal

or Create an Account

Close Modal
Close Modal